Canadian Natural Resources Ltd (CNQ)vsVertex Pharmaceuticals Inc (VRTX)
CNQ
Canadian Natural Resources Ltd
$49.02
+1.32%
ENERGY · Cap: $102.25B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Canadian Natural Resources Ltd generates 223% more annual revenue ($38.76B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 27.9%. VRTX appears more attractively valued with a PEG of 2.19. CNQ earns a higher WallStSmart Score of 67/100 (B-).
CNQ
Strong Buy67
out of 100
Grade: B-
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+76.9%
Fair Value
$175.97
Current Price
$49.02
$126.95 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 2.3B in free cash flow
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
3.7% earnings growth
Expensive relative to growth rate
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CNQ
The strongest argument for CNQ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 27.9% and operating margin at 19.6%.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : CNQ
The primary concerns for CNQ are Revenue Growth, EPS Growth, PEG Ratio.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CNQ profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CNQ carries more volatility with a beta of 1.06 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
CNQ generates stronger free cash flow (2.3B), providing more financial flexibility.
Bottom Line
CNQ scores higher overall (67/100 vs 66/100), backed by strong 27.9% margins. VRTX offers better value entry with a 36.5% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Canadian Natural Resources Ltd
ENERGY · OIL & GAS E&P · USA
Canadian Natural Resources Limited acquires, explores, develops, produces, markets and sells crude oil, natural gas and natural gas liquids (NGL). The company is headquartered in Calgary, Canada.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other OIL & GAS E&P Stocks
Want to dig deeper into these stocks?